Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01220115 · ClinicalTrials.gov registry record
A 3-year, Prospective, Non-interventional, Multicenter Registry in Sickle Cell Disease (SCD) Patients
A clinical trial of Sickle Cell Disease, sponsored by Novartis.
- Completed
- Registry status
- 498
- Enrollment target
- 20
- Study locations
NCT01220115: Completed study of Sickle Cell Disease, sponsored by Novartis.
NCT01220115 is a study of Sickle Cell Disease that has completed, run by Novartis. The registered enrollment target is 498 participants, above the 290-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (72% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01220115, a study of Sickle Cell Disease, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- 498 participants
- Enrollment target
- 20
- Study locations
Study Summary
A long term observational study in sickle cell disease will enhance the understanding of the disease patterns, current transfusion practices, treatments and outcomes in sickle cell disease.
Conditions Studied
Study Locations (20)
Florida
- Broward Oncology Associates, P.A. - Fort Lauderdale
- Miami Children's Hospital - Miami
- Innovative Medical Research - Miami
- M.D. Anderson Cancer Center Orlando - Orlando
- All Children's Hospital - St. Petersburg
- Central Tampa Hematology and Oncology Associates - Tampa
- St. Joseph Children's Hospital - Tampa
California
- Children's Hospital Oakland (CHO) - Oakland
- Children's Hospital of Orange County Sickle Cell Disease Center - Orange
- Rady Children's Hopsital / UC San Diego University Hospital Sickle Cell Disease Center - San Diego
Illinois
- University of Illinois at Chicago, Dept of Pediatrics - Chicago
- Abington Hematology Oncology Associates, Inc - Oak Lawn
Louisiana
- Tulane University School of Medicine - New Orleans
- LSU Department of Pediatrics Children's Hospital - New Orleans
Maryland
- Johns Hopkins University Division of Hematology - Baltimore
- Oncology-Hematology Associates, P.A. - Clinton
Arkansas
- Hematology Oncology Services of Arkansas - Little Rock
Connecticut
- Hematology Oncology, P.C. - Stamford
District of Columbia
- Howard University - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 498 participants |
| Start Date | 2010-01 |
| Est. Completion | 2014-09 |
What the finished NCT01220115 record still lists
NCT01220115 is an observational study that tracks outcomes without assigning an intervention. The registered 498 participants enrollment target is mid-sized for trials with a published cap, above the 290-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (72% higher).
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 0 interventions.
NCT01220115 names 20 study sites across 9 states, led by Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT01220115 about?
NCT01220115 is a clinical study titled "A 3-year, Prospective, Non-interventional, Multicenter Registry in Sickle Cell Disease (SCD) Patients". A long term observational study in sickle cell disease will enhance the understanding of the disease patterns, current transfusion practices, treatments and outcomes in sickle cell disease.
What is the current status of trial NCT01220115?
This trial is currently completed. The enrollment target is 498 participants. The study started on 2010-01. Estimated completion is 2014-09.
What conditions does trial NCT01220115 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
Who is sponsoring clinical trial NCT01220115?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01220115 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01220115's enrollment target sits among peer trials
498 7th of 213 higher than 207 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Early Life Exposures Among Children With Sickle Cell Disease
RECRUITING · NA
-
Exercise in Child Health
RECRUITING · NA
-
Sickle Cell Children's Exercise Study (SuCCESs)
RECRUITING · NA
-
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
RECRUITING · Phase 1
-
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04137900 · 499 participants · Phase 1
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
- NCT06733480 · 499 participants · NA
Innovating Physical Therapy: A Pilot Study on Band Connect's Impact on Compliance, Satisfaction, and Revenue
- NCT03175224 · 497 participants · Phase 2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- NCT05301816 · 497 participants · NA
PDN Post Market, Multicenter, Prospective, Global Clinical Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia